Objectives: To study the role of the neutrophil-to-lymphocyte ratio in predicting survival outcomes for patients with advanced bladder cancer. Methods: We retrospectively reviewed 150 patients diagnosed with advanced or metastatic bladder cancer between January 2004 and June 2014. The neutrophil-tolymphocyte ratio was computed on diagnosis and after the first cycle of chemotherapy. A neutrophil-to-lymphocyte ratio cut-off of 3.0 was determined, with a concordance index of 0.89. Kaplan-Meier curves, log-rank tests, Cox proportional hazards and logistic regression models were used to predict the association of the neutrophil-to-lymphocyte ratio with survival outcomes. Results: Just five patients were alive at the end of the study; the rest died from metastatic bladder cancer. On multivariate analysis, higher Eastern Cooperative Oncology Group status, lymphadenopathy, visceral metastases and neutrophil-to-lymphocyte ratio ≥3.0 were associated with poorer overall survival (hazard ratio 1.67, P = 0.03; hazard ratio 1.97, P = <0.01; hazard ratio 2.02, P = <0.01; hazard ratio 5.06, P = <0.01), whereas chemotherapy conferred better overall survival (hazard ratio 0.546, P = 0.01). Furthermore, the role of chemotherapy prolonged survival longer in patients with a neutrophil-to-lymphocyte ratio <3.0 (median overall survival 13.0 vs 22.0 months, hazard ratio 0.273, P = 0.008) compared with a neutrophil-to-lymphocyte ratio ≥3.0 (median overall survival 4.0 vs 7.0 months, hazard ratio 0.452, P = 0.020). More importantly, when dichotomized to the four different pre-and post-chemotherapy groups, patients with a pre-and post-chemotherapy neutrophil-to-lymphocyte ratio <3.0 had the best additional median overall survival of 19.0 months compared with patients with a preand post-chemotherapy neutrophil-to-lymphocyte ratio ≥3.0 (3.0 months). Conclusions: Elevated neutrophil-to-lymphocyte ratio is independently associated with poorer chemotherapeutic response and overall survival in patients with advanced or metastatic bladder cancer. The neutrophil-to-lymphocyte ratio can be an inexpensive novel factor in prognosticating disease progression and providing better patient counseling.
Introduction
Advanced/metastatic bladder cancer remains one of the most challenging oncological tumors. According to the American Cancer Society 1 and Cancer Research UK, 2 5-year overall survival remains at a dismal~10%. Even with the establishment of cisplatin-based chemotherapy regimes, the median survival time approximates 14 months, with significant heterogenity in clinical outcomes amongst these patients. 3, 4 These poor outcomes suggests the need for continual developments in understanding the tumor biology and better risk stratification.
Interestingly, there has been increasing evidence supporting the role of inflammation in cancer development and progression, 5 and the NLR has been identified as a marker of tumor activity. 6 The inflammatory changes are hypothesized to induce changes in the cancer microenvironment, which aid tumor proliferation, migration and angiogenesis. 7 A higher NLR has been previously shown to be associated with poorer disease-specific and overall survivals in gastric, hepatic, non-small cell and cervical cancer. [8] [9] [10] More recent studies have reproduced similar associations in patients with localized bladder cancer undergoing curative radical cystectomy.
However, there remains limited data on the prognostic role of NLR in predicting clinical outcomes of patients with advanced cancers. Previous studies have explored the role of NLR in advanced lung cancer 14 and colorectal cancers, 15 and yielded positive associations. Given the immunological nature of bladder cancers, we believe that NLR can be an inexpensive and readily available biomarker in prognosticating survival outcomes in patients with advanced/metastatic bladder cancers.
Methods
After institutional review board approval, we retrospectively reviewed Singapore General Hospital's cancer registry database and identified 248 patients diagnosed with advanced or metastatic bladder cancer from January 2004 to June 2014. These patients had either locally advanced disease (cT4bN0M0), lymph node involvement (TxN1-3M0) or metastatic disease (TxNxM1). A total of 98 patients were excluded from the study; 48 had concomitant infections and eight had inflammatory conditions (three rheumatoid arthritis, two systemic lupus erythematosus, two psoriasis and one Sj€ ogren's disease) that could confound the NLR value; 38 patients had incomplete information on chemotherapy drug regimes and timing of subsequent blood tests, and four foreign patients were lost to follow up.
All patients had histological confirmation of urothelial bladder cancer by biopsy or transurethral resection of bladder tumor. They subsequently underwent staging scans with computed tomographies of the thorax, abdomen and pelvis to confirm the extent of disease. Additional adjunctive imaging modalities, such as bone scan, magnetic resonance imaging and positron emission tomography, were considered based on the patients' symptoms or deemed necessary by the attending physician.
Hematological and biochemical blood results were collected within 12 days after staging scans confirmed the diagnosis of advanced/metastatic bladder cancer. We defined leukocytosis as total white counts ≥12 000/mm 3 , anemia as hemoglobin <12.5 g/dL for women and <13.5 g/dL for men, and hypoalbuminemia as <35 g/dL. No patient received chemotherapy before these blood results. NLR was analyzed as a continuous variable and a cut-off point of 3.0 was obtained, with a statistical receiver operating characteristic of 0.892 ( Fig. 1) . At this cut-off of 3.0, the sensitivity was 87.3%, specificity was 85.0%, positive predictive value was 94.1% and negative predictive value was 70.8%.
Outcome measures
A total of 60 patients underwent and completed at least one cycle of chemotherapy, whereas the other 90 declined chemotherapy. The main reasons for refusal of chemotherapy were poor functional status, significant comorbidities and patients' personal decisions. The post-chemotherapy NLR changes were derived from the blood tests carried out before commencement of the second chemotherapy cycle. Given the retrospective nature of this study, coupled with the heterogeneity of physicians' practices, patients' preferences and cost issues, subsequent follow-up plans were not consistently standardized. Singapore General Hospital recommended routine blood tests before commencement of each cycle of chemotherapy, with an outpatient visit at a 1-month interval (approximately the completion of three cycles of chemotherapy) to review patients' symptoms and arrange for interval scans to review the disease progression. Subsequent follow up ranged from 1 to 3 monthly depending on the patient's chemotherapeutic response and physicians' discretions. The primary outcome was overall survival, measured from time of diagnosis of advanced/metastatic disease through staging scans until the time of death or last follow up. The additional overall survival after chemotherapy was measured from the time of follow-up blood test (before commencement of second cycle of chemotherapy) to the time of death or last follow up.
Statistical analyses were carried out using SPSS v20 (IBM, Armonk, NY, USA). The relationship between clinicopathological features and NLR was calculated with the v 2 -test and Wilcoxon test as appropriate. For univariate analysis, Kaplan -Meier analysis of the effect of each factor on survival was carried out, and the significance of each factor was tested using the log-rank test. Multivariate Cox proportional hazard and logistics regression models were used to evaluate the association of NLR with survival outcomes, after adjusting for other clinicopathological factors. All tests were two-sided, with P < 0.05 considered to be statistically significant.
Results
The patients' demographics and tumor characteristics are shown in Table 1 . There were 122 men (81.3%) and 28 women (28.7%), with a median age of 70 years at diagnosis (IQR 63-77). A total of 17 patients (11.3%) had locally advanced disease, and 101 patients (67.3%) had lymph node involvement, of which 34 patients (22.7%) had lymph nodeconfined disease. A total of 99 patients (66.0%) had metastatic disease, with lungs being the most common site of 
Pre-chemotherapy NLR and survival outcome
The median follow-up time was 8.5 months (IQR 2.8-29.0), owing to the aggressive nature of bladder cancer and high mortality rate. Just five patients were alive at the end of the study; the rest died from and were signed up as metastatic bladder cancer from the registry. On univariate analysis, older age (≥65 years), poorer ECOG status, lymph node involvement, metastasis, hypoalbuminemia and a high pre-chemotherapy NLR (≥3.0) were associated with worse overall survival ( Table 2 ). In particular, of all the metastatic sites, liver metastasis was associated with the worst overall survival (HR 1.56, 95% CI 1.12-2.48, P = 0.048). We next assessed by multivariate analysis and found that high pre-chemotherapy NLR (≥3.0) remained independently associated with worse overall survival (HR 5.06, 95% CI 2.88-8.88, P < 0.001). The median overall survival for patients with NLR ≥3.0 was 5.0 months (IQR 3.0-8.0), but was significantly more optimistic for patients with NLR <3.0 at 15.5 months (IQR 12.2-27.0; Fig. 2 ). Meanwhile, other variables, which included poorer ECOG status, lymph node involvement, metastasis and absence of chemotherapy, were also independently associated with a poorer survival (HR 1.67, 95% CI 1.05-2.67, P = 0.032; HR 1.97, 95% CI 1.25-3.12, P = 0.004; HR 2.02, 95% CI 1.26-3.26, P = 0.004), whereas patients who underwent chemotherapy had a better prognosis (HR 0.546, 95% CI 0.342-0.872, P = 0.011).
On subgroup analysis of patients with NLR ≥3.0 and <3.0, we found that although chemotherapy was associated with better survival outcome in both groups, patients with NLR <3.0 undergoing chemotherapy had a better median overall survival (22.0 vs 13.0 months, HR 0.273, 95% CI 0.105-0.711, P = 0.008; Fig. 3a ) compared with patients with NLR ≥3.0 undergoing chemotherapy (7.0 vs 4.0 months, HR 0.451, 95% CI 0.232-0.881, P = 0.020) (Fig. 3b) .
Post-chemotherapy NLR and survival outcome
When the two pre-chemotherapy NLR groups were assigned together with their subsequent post-chemotherapy NLR values, four different groups of patients were introduced: low-low (pre-chemotherapy NLR <3.0 and post-chemotherapy NLR <3.0) in 17 patients (28.3%), low-high (pre-chemotherapy NLR <3.0 and post-chemotherapy NLR 
Discussion
In the present retrospective review of our institution's cohort of advanced/metastatic bladder cancer, we have shown that high NLR is an important predictor of poorer overall survival. The change in NLR after chemotherapy further predicts the additional survival outcome in these patients. These findings remained significant after controlling for the various clinicopathological variables, suggesting that NLR is independently associated with adverse outcomes. The role of inflammation in tumor progression has been gaining populance in recent years. 16 Schepisi et al. presented a very comprehensive discussion on the strong relationship between the role of immune system and inflammatory processes on the clinical outcome of patients with urothelial cancer. 17 He detailed the pathophysiology between cytokines and NLR in tumor biology. A heightened circulating neutrophil level is associated with increased cytokines, particularly interleukins (IL-1, IL-6) and pro-angiogenic vascular endothelial growth factor, which promote tumor migration and proliferation. 18 IL-6 protects the cancer cells from therapy-induced DNA damage, oxidative stress and apoptosis, hence promoting tumorigenesis. 19 Furthermore, the release of reactive oxygen species further compromises T-cell function. 20 In contrast, a relative leukocytopenia, in particular cytotoxic T cells that are capable of targeted apoptotic cancer cell death, represents a weakened adaptive immune response to malignancy. 21 Hence, the combinatory effects of these two cellular mechanisms, or the NLR, might explain the tumor biology in cancers and predict survival outcomes.
The role of NLR in predicting survival outcomes was first described in many non-urological malignancies, such as gastric, hepatic, non-small cell and cervical cancer. [8] [9] [10] In recent years, new studies have similarly established the significance of NLR in urological malignancies similarly. Ohno et al. reviewed 198 patients who underwent radical nephrectomy, and found a significant difference in 5-year recurrence-free survival between NLR <2.7 (94%) and ≥2.7 (74%; P = 0.020). 22 Jang et al. evaluated 2067 patients with prostate cancer undergoing radical prostatectomy, and commented that a higher preoperative NLR (≥1.76) predicted poorer cancer-specific survical and overall surival. 23 Viers evaluated that in patients with urothelial bladder cancer undergoing radical cystectomy, higher preoperative NLR was associated with greater extravesical disease, lymph node involvement, higher recurrence rates, and poorer cancer-specific survical and overall surival. 13 However, most studies are based on the role of NLR in curative treatments for urological malignancies. In metastatic urological tumors, in particularly bladder cancers, where the progression is often rapid with dismal prognosis, NLR could be useful in understanding the tumor biology and stratifying patients' survival outcomes. Furthermore, Templeton et al., in his meta-analysis of 100 studies, comprising 40 559 patients, evaluated that the association between NLR and poorer prognosis was stronger for metastatic than non-metastatic disease, and this could possibly reflect the greater tumor burden and a chronic weakened immune response towards cancer cells. 24 To date, just two recent studies (2015) have evaluated the role of NLR in metastatic urothelial cancers. Rossi et al. commented that NLR ≥3.0 was associated with poorer progressionfree survival (3.2 vs 6.9 months) and poorer overall survival (5.7 vs 13.1 months). 25 They also examined the pre-therapy and follow-up NLR after chemotherapy, and showed that the low-low group had the best prognosis, whereas the high-high group had the worst prognosis. However, patients with lowhigh NLR after chemotherapy were excluded from the analysis. Taguchi et al. attempted to develop a prognostic model based on NLR ≥3.0, ECOG and liver metastasis. 26 However, both studies only included patients who underwent chemotherapy. They did not address a large group of patients who declined chemotherapy. This is especially relevant in the Asian demographic, where many patients have reserved considerations regarding chemotherapy and might often prefer alternative medicine. Similarly, both studies examined urothelial cancers collectively, regardless of the site of tumor, which might not entirely reflect the tumor biology unique to bladder, ureteral, urethral or renal pelvic cancers. In particular, in the study by Rossi et al., the definition of advanced urothelial cancer was not clearly defined. The selection of variables for multivariate analyses was not elaborated or discussed. Also, the study did not specifically look into the relationship between NLR and chemotherapeutic response, nor did it provide any information on how NLR could provide better decision-making when treating advanced/metastatic bladder cancers. These were questions that we had set out to discuss in our study. In contrast, in the study by Taguichi et al., more than one-quarter of patients had previously undergone chemotherapy, which could have affected the initial derivation of NLR value. Taguichi also attempted to develop a prognostic model to predict survival outcomes, but the difference in the relative risk of each of the variables (NLR, ECOG status and liver metastasis) was not considered. An risk-adjusted ratio model would have been more accurate to predict survival outcomes.
The cut-off for NLR value remains divided. While most studies on urothelial malignancies considered a cut-off value between 2.7 and 3.0, Templeton et al. also commented that the decisions behind certain NLR values were not well elaborated. 24 Also, the heterogeneity of NLR thresholds might suggest variations in host response at different disease stages and population groups. 12 In the present study, NLR was analyzed as a continuous variable, with a receiver operating characteristic, or concordance index, of 0.892, which suggests a very strong accuracy of the predictive role of NLR. This concordance index of 0.892 is also the highest achieved value to date in the literature.
Furthermore, unlike most studies that focused on the pretreatment NLR value, the present study is unique because it factored in the change in NLR post-therapy, and this might represent a more dynamic understanding of the change in host response towards the tumor cells, especially after chemotherapy. Coupled with the pretreatment NLR value, we are better equipped to provide more realistic expectations and survival outcomes for patients at different junctures. First, at the initial presentation of advanced/metastatic bladder cancer, we now know that patients with low NLR (<3.0) have a longer overall survival (median 15.5 vs 5.0 months). Second, patients can be counseled that chemotherapy does prolong survival in all patients, although the survival benefit is much guarded in those with a higher NLR ≥3.0 (3.0 months) compared with those with NLR <3.0 (9.0 months). As such, for the patients with low NLR (<3.0) at diagnosis and declined chemotherapy, they should be strongly encouraged and reconsidered for upfront chemotherapy, for they would have the best prognosis. Given the predominant aversion towards chemotherapy in Asian culture, physicians should make a concerted effort to convince this group of patients of the significant survival benefit with chemotherapy.
More importantly, for those who underwent and completed first-line chemotherapy, patients with persistently low NLR (low-low group) had the best prognosis. They might have a more favorable tumor biology and should be considered for additional chemotherapy. Patients with a low-high NLR after the first cycle of chemotherapy present a more challenging conundrum, because they reflect a poorer chemotherapeutic response and subsequent overall survival. However, we feel that in this group of otherwise fit individuals, further chemotherapy should still be considered, and further interval assessment of subsequent NLR values and staging scans would provide more information on the risk-to-benefit ratio of the continuation of chemotherapy. In contrast, patients with a high-low NLR should also be considered for further chemotherapy, given that the drop in NLR would suggest a favorable chemotherapeutic response. Patients with persistently high NLR despite chemotherapy (high-high group) have the worst prognosis, with a dismal additional overall survival of 3.0 months. Best supportive care should also be considered early, and expectations have to be carefully managed for these patients and their family members.
We acknowledge that the present study was limited by its retrospective and non-randomized nature. Furthermore, just 60 patients (40%) underwent chemotherapy during the 10-year period. However, this small sample size also reflects the apprehensive nature of most conservative Asian populations, who lack information and conviction towards chemotherapy, and often consider alternative medicine. We hope that the present study, carried out within an Asian society, with robust analyses and results, can challenge and convince the role of chemotherapy in advanced/metastatic bladder cancers within our region. Finally, we recognize that the results are derived from a single tertiary institution and further external validation will be required. We hope to encourage more research in the field of prognosticating survival outomes in advanced/metastatic urological malignancies.
Elevated NLR is independently associated with poorer overall survival and chemotherapeutic response in patients with advanced/metastatic urothelial bladder cancer, after controlling for other clinicopathological features. Post-chemotherapy NLR changes further stratifies survival outcomes in these patients. These results suggest that NLR can be a reliable and inexpensive biomarker in predicting survival outcomes in patients with advanced/metastatic bladder cancer.
